Sugi Predict

Sugi Predict / Compounds / SCHEMBL12293097

SCHEMBL12293097

SCHEMBL12293097

CC(C)(C)c1cccc(S(=O)(=O)N2CCCC2)c1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.64
▸ GAA P10253 2/20 0.64
▸ ALDH1A1 P00352 8/20 0.63
▸ SMN1; SMN2 Q16637 2/20 0.63
▸ MEN1 O00255 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ TSHR P16473 3/20 0.58
▸ NPSR1 Q6W5P4 2/20 0.58
▸ THRB P10828 1/20 0.58
▸ HTT P42858 3/20 0.56
▸ MAPT P10636 1/20 0.55
▸ IL1RN P18510 1/20 0.55
▸ KDM4E B2RXH2 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ USP2 O75604 2/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL270805 0.98 LMNA (0.67) LMNAGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL14349612 0.97 LMNA (0.59) LMNAGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL14329281 0.93 HTT (0.57) LMNAGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL270811 0.88 POLB (0.61) LMNAGAAALDH1A1SMN1; SMN2TSHR
SCHEMBL10145044 0.86 ALDH1A1 (0.62) LMNAALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL27370216 0.84 HTT (0.70) LMNAGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL12111072 0.84 ALDH1A1 (0.58) LMNAGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL29944227 0.83 HTT (0.68) LMNAGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL14625303 0.83 HTT (0.68) LMNAGAAALDH1A1SMN1; SMN2MEN1
SCHEMBL12169363 0.80 LMNA (0.96) LMNAGAAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10941160-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2021-03-09 — — US disclosed
US-20200148703-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2020-05-14 — — US disclosed
US-10562915-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2020-02-18 — — US disclosed
US-10023592-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-17 — — US disclosed
US-10023592-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-17 — — US disclosed
US-20170158709-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2017-06-08 — — US disclosed
US-20170158709-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2017-06-08 — — US disclosed
US-9598372-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2017-03-21 — — US disclosed
US-9598372-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2017-03-21 — — US disclosed
US-20160115134-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-04-28 — — US disclosed
US-9115114-B2 Bromodomain inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-08-25 — — US disclosed
US-20150183784-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-07-02 — — US disclosed
US-9034900-B2 Bromodomain inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-05-19 — — US disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed
US-20110224231-A1 Novel Lactams as Beta Secretase Inhibitors PFIZER INC. (US) 2011-09-15 — — US disclosed
US-20090143412-A1 FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER HEALTHCARE LLC (US) 2009-06-04 — — US disclosed
US-7429584-B2 Furo[2.3-b]pyridine derivatives for the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION (US) 2008-09-30 — — US disclosed
US-7312209-B2 Acridone inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-25 — — US disclosed
US-7312209-B2 Acridone inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158709-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 LMNA 1464/4885GAA 2844/4885ALDH1A1 3316/4885
US-20090143412-A1 FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS NCOR1, NR3C1, NR3C2 LMNA 4231/4885GAA 4541/4885ALDH1A1 668/4885
US-10562915-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 LMNA 1464/4885GAA 2844/4885ALDH1A1 3316/4885
US-20150111885-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 LMNA 1464/4885GAA 2844/4885ALDH1A1 3316/4885
US-10023592-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 LMNA 1464/4885GAA 2844/4885ALDH1A1 3316/4885
US-10941160-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 LMNA 1464/4885GAA 2844/4885ALDH1A1 3316/4885
US-20150183784-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 LMNA 1464/4885GAA 2844/4885ALDH1A1 3316/4885
US-20200148703-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 LMNA 1464/4885GAA 2844/4885ALDH1A1 3316/4885
US-20110224231-A1 Novel Lactams as Beta Secretase Inhibitors BACE1, BACE2, APH1B LMNA 1235/4885GAA 27/4885ALDH1A1 2135/4885
US-20160115134-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 LMNA 1464/4885GAA 2844/4885ALDH1A1 3316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback